5-methylcytosine promotes pathogenesis of bladder cancer through stabilizing mRNAs

Xin Chen,Ang Li,Bao-Fa Sun,Ying Yang,Ya-Nan Han,Xun Yuan,Ri-Xin Chen,Wen-Su Wei,Yanchao Liu,Chun-Chun Gao,Yu-Sheng Chen,Mengmeng Zhang,Xiao-Dan Ma,Zhuo-Wei Liu,Jun-Hang Luo,Cong Lyu,Hai-Lin Wang,Jinbiao Ma,Yong-Liang Zhao,Fang-Jian Zhou,Ying Huang,Dan Xie,Yun-Gui Yang
DOI: https://doi.org/10.1038/s41556-019-0361-y
IF: 21.3
2019-07-29
Nature Cell Biology
Abstract:Although 5-methylcytosine (m<sup>5</sup>C) is a widespread modification in RNAs, its regulation and biological role in pathological conditions (such as cancer) remain unknown. Here, we provide the single-nucleotide resolution landscape of messenger RNA m<sup>5</sup>C modifications in human urothelial carcinoma of the bladder (UCB). We identify numerous oncogene RNAs with hypermethylated m<sup>5</sup>C sites causally linked to their upregulation in UCBs and further demonstrate YBX1 as an m<sup>5</sup>C 'reader' recognizing m<sup>5</sup>C-modified mRNAs through the indole ring of W65 in its cold-shock domain. YBX1 maintains the stability of its target mRNA by recruiting ELAVL1. Moreover, NSUN2 and YBX1 are demonstrated to drive UCB pathogenesis by targeting the m<sup>5</sup>C methylation site in the <i>HDGF</i> 3′ untranslated region. Clinically, a high coexpression of NUSN2, YBX1 and HDGF predicts the poorest survival. Our findings reveal an unprecedented mechanism of RNA m<sup>5</sup>C-regulated oncogene activation, providing a potential therapeutic strategy for UCB.
cell biology
What problem does this paper attempt to address?